Updates in EGFR-Mutant Advanced NSCLC – First- and Second-Line Treatment

home / investigator-perspectives / updates-in-egfr-mutant-advanced-nsclc-first-and-second-line-treatment

Hatim Husain, MD, discusses how recent updates on acquired resistance mechanisms and overall survival data for combination therapies involving amivantamab, lazertinib, and chemotherapy in EGFR-mutated NSCLC patients progressing after first-line osimertinib treatment are shaping the evolving treatment landscape and influencing clinical decision-making.

1 KOL is featured in this series.

EP. 1: Acquired Resistance to Kinase Inhibitors - EGFR- mutated Non-Small Cell Lung Cancer

Hatim Husain, MD
September 30th 2024

Hatim Husain, MD, discusses how acquired resistance to kinase inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) poses a significant challenge in long-term treatment efficacy, necessitating ongoing research into novel therapeutic strategies and combination approaches to overcome resistance mechanisms.

Watch